Smart Nanocarriers for Drug Delivery in Colon Cancer
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 3072
Special Issue Editors
Interests: nanomedicine; nanotechnology; nanomaterials; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals
Interests: nanomedicine; nanotechnology; nanomaterials; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals
Interests: nanomedicine; nanotechnology; nanomaterials; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite advances in the diagnosis and treatment of colorectal cancer, its incidence is increasing at an alarming rate, and it is currently the third most common cause of cancer-related death worldwide. As with most solid tumors, one of the most challenging issues in colon cancer therapy is associated with the severe side toxicity of chemotherapeutic drugs. Thus, there is an urgent need to reproducibly develop effective targeted nanocarriers capable of preventing drug adsorption and degradation in the upper gastrointestinal tract, and thus capable of transporting chemotherapeutic drugs to the colon.
This Special Issue aims to collect recent trends in the field of colon cancer therapy related to the use of nanocarriers capable of promoting active targeting in the tumor microenvironment. Thus, we welcome articles on the development, characterization and validation of liposomes, nanoparticles, nanohydrogels and nanocomposites conjugated with selective targeting molecules and/or stimuli-responsive, designed to improve the main drawbacks of traditional chemotherapy.
Dr. Milena A. Vega
Dr. Celia Nieto
Dr. Gema Marcelo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liposomes and lipid-based formulations
- polymeric and metal nanoparticles
- hydrogels and nanocomposites
- targeted drug delivery
- smart drug delivery
- controlled drug release
- nanomaterial functionalization
